
Background Hypertension is a major public health concern associated with cardiovascular complications, including heart disease and stroke. This study assessed hypertension knowledge, prevalence, and associated risk factors among civil servants in Osun State, Nigeria. Methods A cross-sectional study was conducted among 305 civil servants selected through multistage sampling. Data were collected using a semi-structured questionnaire and analysed using SPSS version 23. Binary logistic regression examined predictors of hypertension knowledge and selected modifiable risk behaviours. Statistical significance was set at p < 0.05. Results Participants’ mean age was 39.48 ± 7.50 years. Overall, 75.7% had good knowledge of hypertension, while the observed hypertension prevalence was 44.6%. Participants aged 20–39 years had higher odds of good knowledge than those aged 40–59 years (AOR=1.74, 95% CI: 1.02–2.96). Males had higher odds of smoking (AOR=13.58, 95% CI: 1.78–103.64) and alcohol consumption (AOR=3.99, 95% CI: 2.08–7.65). Monogamous respondents had lower odds of alcohol consumption than polygamous respondents (AOR=0.40, 95% CI: 0.20–0.80). Younger age was associated with the physical activity outcome (AOR=0.35, 95% CI: 0.18–0.70). Conclusion Despite good hypertension knowledge, the observed prevalence was substantial. Workplace interventions should extend beyond health education to integrating blood pressure screening, early referral, appropriate management, targeted lifestyle modification. Collaboration between government agencies and occupational health services is essential for implementing sustainable cardiovascular health programmes.
Introduction Intravascular lithotripsy (IVL) and rotational atherectomy (RA) are widely used for plaque modification in calcified coronary lesions, but head-to-head randomized evidence is limited. Prior meta-analyses, based mainly on observational data, suggested an early benefit with IVL. We performed an updated meta-analysis restricted to randomized controlled trials (RCTs). Methods PubMed, Embase and the Cochrane Library were searched through September 2026 for RCTs comparing IVL with RA before stenting of moderately to severely calcified coronary lesions. The primary outcome was major adverse cardiac events (MACE) at 12 months. Binary outcomes were pooled as Peto odds ratios (ORs) with 95% confidence intervals (CIs). Risk of bias was assessed with RoB 2.0 and certainty of evidence with GRADE. Results Four RCTs including 394 patients (193 IVL, 201 RA) were included. MACE did not differ between strategies (OR 1.42, 95% CI 0.56–3.61; I²=0%). No differences were observed in cardiac death (OR 0.52, 95% CI 0.05–5.06), all-cause death (OR 0.77, 95% CI 0.22–2.62), myocardial infarction (MI) (OR 2.76, 95% CI 0.39–19.65), periprocedural MI (OR 0.67, 95% CI 0.01–31.58), target lesion failure (OR 2.76, 95% CI 0.81–9.49), target lesion revascularization (OR 2.69, 95% CI 0.79–9.09) or procedural success (OR 0.46, 95% CI 0.14–1.50). Certainty of evidence was low for all outcomes. Conclusions In randomized evidence, IVL and RA yielded comparable clinical outcomes in calcified coronary lesions eligible for both strategies. Given the small number of trials and sparse events, these findings should be considered hypothesis-generating.
Cardiac arrest (CA) complicating cardiogenic shock (CS) identifies a high-risk phenotype, but population-level mortality trends among patients with both conditions are not well described. Using the CDC WONDER Multiple Cause of Death database, we identified deaths among US adults aged ≥25 years from 1999 to 2024 in which both CA (ICD-10 I46) and CS (R57.0) were recorded on the same death certificate and compared them with all CS-related deaths. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated, and temporal trends were assessed using Joinpoint regression. Overall, 98,531 CA+CS deaths occurred, compared with 577,658 CS-related deaths. The AAMR for CA+CS declined from 1.3 in 1999 to 0.9 in the mid-2000s, rose by 10.1% per year between 2009 and 2021 (95% CI 9.8 to 10.5) to a peak of 2.9, and declined modestly to 2.7 by 2024. The share of CS deaths that also listed CA increased from 12.4% to 18.9%. Men had consistently higher AAMRs than women (3.6 vs 1.9 in 2024), and adults aged ≥65 years accounted for 71.3% of deaths. Non-Hispanic Black adults had the highest rates from 2016 onward and the steepest increase, while the West had the highest and the Midwest the lowest rates among census regions. CA+CS mortality in the United States has roughly doubled since 1999, with persistent differences by sex, race and ethnicity, age, and region that warrant study with clinically detailed data.
Background Tafamidis, approved in 2019, was the first disease-modifying therapy for transthyretin amyloid cardiomyopathy. Disparities in cardiac amyloidosis outcomes remain incompletely characterized. Objectives To characterize US trends in cardiac amyloidosis hospitalizations, subtypes, and risk-adjusted mortality from 2017 to 2022, including changes around tafamidis approval. Methods We analyzed the 2017-2022 National Inpatient Sample, defining cases by an amyloidosis code (E85.x) paired with a heart failure or restrictive cardiomyopathy code. Survey-weighted regression assessed outcomes; Joinpoint and segmented regression tested for a 2019 trend inflection. Results Of an estimated 111,450 hospitalizations, 83 % were coded as Other/Unspecified amyloidosis. In-hospital mortality was 7.1 %, highest in light-chain (AL) amyloidosis (9.4 %) and lowest in wild-type transthyretin amyloidosis (4.9 %; adjusted odds ratio 0.48 vs AL). The age-standardized hospitalization rate nearly doubled, from 4.2 to 8.0 per 100,000 adults, with no inflection detected at 2019. Private and “Other” payer status were associated with higher adjusted mortality than Medicare, the mortality difference for uninsured patients increased over time, and Black patients had lower adjusted odds of pacemaker implantation. Black patients accounted for a larger share of hereditary ATTR admissions than of other subtypes in every year. Conclusions Cardiac amyloidosis hospitalizations rose steadily from 2017 to 2022, and no inflection was detected at the 2019 approval of tafamidis. Because the NIS lacks data on treatment exposure, diagnostic testing, and disease severity, these findings cannot establish whether tafamidis influenced hospitalization trends. Differences in in-hospital mortality by payer and in pacemaker implantation by race persisted and warrant investigation with patient-level clinical data.